It is crucial to estimate the proportion of the total population of persons living with HIV, including those that are not yet diagnosed, in order to understand the burden of HIV and the need for antiretroviral treatment and other HIV-related care.
Dublin Declaration monitoring - 2020 progress
Every second year, ECDC assesses and reports on the progress of the implementation of the Dublin Declaration through a series of thematic report and evidence briefs. Here you can find the 2020 progress reports.
Investing in HIV response essential to curb on-going HIV transmission in Europe.Archived
New data for 2011 show that more than 121 000 new HIV cases were reported in the WHO European Region, including more than 28 000 new infections in the European Union and the European Economic Area (EU/EEA), indicating an increase for the whole Region compared to the previous year1.
ECDC Vaccine Scheduler
The Vaccine Scheduler is an interactive tool that shows vaccination schedules for individual EU/EEA countries and specific age groups.
- Hepatitis A
- Hepatitis B
- Human papillomavirus infection
- Influenza in humans, seasonal
- Invasive Haemophilus influenzae disease
- Meningococcal disease
- Pneumococcal disease
- Prevention and control
- Rotavirus infection
- Tick-borne diseases
Response plan to control and manage the threat of multidrug-resistant gonorrhoea in Europe
This response plan is designed to prevent the spread of multidrug-resistant Neisseria gonorrhoeae (MDR NG) in the EU/EEA in the context of the possible emergence of untreatable gonorrhoea
Review of Chlamydia Control Activities in EU Countries
This report illustrates the scope and the findings of Project SCREen, arguably the biggest study to date on chlamydia control activities in the EU. In addition to data from EU Member States, SCREen also collected data from EU candidate countries, EFTA member states, and the USA.
Novel approaches to testing for sexually transmitted infections, including HIV and hepatitis B and C in Europe
This report focuses on novel approaches to testing for sexually transmitted infections, human immunodeficiency virus, hepatitis B virus and hepatitis C virus that are relevant for the prevention and control of these infections at EU/EEA level.